GLP-1 mimetics have been used clinically for over 10 yr [19], but with the current sharp rise in the worldwide incidence of both T2D and obesity [20], there is a pressing need to develop more effective drugs with fewer associated side effects. This evidence concerns the gene GLP1R and obesity disorder.